Diabetes Metab J.  2011 Feb;35(1):23-25. 10.4093/dmj.2011.35.1.23.

What Is the Optimal Monotherapy in Korean Drug-Naive Type 2 Diabetic Patients?: The Practical Evidence of Antidiabetic Monotherapy Study

• Choi JH
• Lee WY

• KMID: 2281488
• DOI: http://doi.org/10.4093/dmj.2011.35.1.23

Abstract

No abstract available.

Reference

1. Korea Health and Welfare Ministry. 2001 The Korean national health nutrition examination survey. 2003. Seoul: Korea Health and Welfare Ministry.

2. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006. (1):CD002967.

3. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996. 334:574–579.

4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998. 352:854–865.

5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. 346:393–403.

6. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004. 351:1106–1118.

7. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. 2007. 357:28–38.

8. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007. 30:2148–2153.

9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007. 356:2457–2471.

10. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007. 298:1189–1195.

11. Bloomgarden ZT. Approaches to treatment of type 2 diabetes. Diabetes Care. 2008. 31:1697–1703.

12. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005. 366:1279–1289.

13. Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, Pogach LM. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care. 2007. 30:1689–1693.

14. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992. 15:737–754.

15. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, ONeill MC, Zinman B, Viberti G. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006. 355:2427–2443.

16. Pala L, Monami M, Lamanna C, Cresci B, Colombi C, Bardini G, Sposato J, Marchionni N, Rotella CM, Mannucci E. Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetol. 2010. 47:Suppl 1. 7–11.

17. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002. 25:330–336.

18. Yoon KH, Shin JA, Kwon HS, Lee SH, Min KW, Ahn YB, Yoo SJ, Ahn KJ, Park SW, Lee KW, Sung YA, Park TS, Kim MS, Kim YK, Nam MS, Kim HS, Park IB, Park JS, Woo JT, Son HY. Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in Korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J. 2011. 35:26–33.